Loading company…
OGD2 Pharma develops cancer immunotherapies that target O-acetylated GD2, including for neuroblastoma and melanoma.
Founded in 2014 and headquartered in Nantes, France, OGD2 Pharma SAS develops monoclonal antibody immunotherapies that bind O-acetylated GD2 (OAcGD2), a target found in pediatric and adult cancers such as neuroblastoma, glioma, sarcoma and melanoma. The company works with pharmaceutical partners and clinical institutions. It plans new immunotherapies and entry into North America and Asia by 2025. Remora Capital acquired the company in October 2016, with deal financials not disclosed.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in